S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
Log in

NASDAQ:FREQFrequency Therapeutics Stock Price, Forecast & News

$23.73
+1.15 (+5.09 %)
(As of 08/11/2020 02:51 PM ET)
Add
Compare
Today's Range
$22.18
Now: $23.73
$24.03
50-Day Range
$20.54
MA: $22.17
$23.25
52-Week Range
$11.17
Now: $23.73
$28.78
Volume3,735 shs
Average Volume129,718 shs
Market Capitalization$735.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which has completed a phase I/II clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FREQ
CUSIPN/A
CIKN/A
Phone866-389-1970

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.95 million
Book Value$5.44 per share

Profitability

Miscellaneous

Employees33
Market Cap$735.87 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
$23.73
+1.15 (+5.09 %)
(As of 08/11/2020 02:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FREQ News and Ratings via Email

Sign-up to receive the latest news and ratings for FREQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Frequency Therapeutics (NASDAQ:FREQ) Frequently Asked Questions

How has Frequency Therapeutics' stock been impacted by Coronavirus?

Frequency Therapeutics' stock was trading at $18.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FREQ shares have increased by 28.3% and is now trading at $23.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Frequency Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Frequency Therapeutics
.

When is Frequency Therapeutics' next earnings date?

Frequency Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Frequency Therapeutics
.

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics (NASDAQ:FREQ) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The company had revenue of $7.26 million for the quarter.
View Frequency Therapeutics' earnings history
.

What price target have analysts set for FREQ?

4 brokerages have issued 12-month price targets for Frequency Therapeutics' shares. Their forecasts range from $27.00 to $36.00. On average, they expect Frequency Therapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 30.5% from the stock's current price.
View analysts' price targets for Frequency Therapeutics
.

Has Frequency Therapeutics been receiving favorable news coverage?

Headlines about FREQ stock have trended neutral recently, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Frequency Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Frequency Therapeutics
.

Who are some of Frequency Therapeutics' key competitors?

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Mfg. (TSM), Akero Therapeutics (AKRO), Brainstorm Cell Therapeutics (BCLI), Beyond Meat (BYND), Chewy (CHWY) and Clovis Oncology (CLVS).

Who are Frequency Therapeutics' key executives?

Frequency Therapeutics' management team includes the following people:
  • Mr. Marc A. Cohen, Exec. Chairman (Age 56)
  • Mr. David L. Lucchino, Co-­Founder, CEO, Pres, Treasurer, Sec. & Director (Age 50)
  • Dr. Christopher R. Loose, Co­- Founder & Chief Scientific Officer (Age 39)
  • Mr. Will McLean, Co-­Founder and VP of Biology & Regenerative Medicine
  • Mr. Richard J. Mitrano, VP of Fin. & Operations (Age 49)

When did Frequency Therapeutics IPO?

(FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Frequency Therapeutics' stock symbol?

Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ."

Who are Frequency Therapeutics' major shareholders?

Frequency Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Matthews International Capital Management LLC (1.54%), HighTower Advisors LLC (0.34%), Russell Investments Group Ltd. (0.23%), Alps Advisors Inc. (0.14%), Cresset Asset Management LLC (0.12%) and New York State Common Retirement Fund (0.11%). Company insiders that own Frequency Therapeutics stock include Christopher R Loose, David L Lucchino, James E Flynn, Joel S Marcus and Marc A Cohen.
View institutional ownership trends for Frequency Therapeutics
.

Which major investors are selling Frequency Therapeutics stock?

FREQ stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Frequency Therapeutics company stock in the last year include Christopher R Loose, David L Lucchino, and Joel S Marcus.
View insider buying and selling activity for Frequency Therapeutics
.

Which major investors are buying Frequency Therapeutics stock?

FREQ stock was bought by a variety of institutional investors in the last quarter, including HighTower Advisors LLC, Russell Investments Group Ltd., Matthews International Capital Management LLC, Cresset Asset Management LLC, New York State Common Retirement Fund, Chilton Investment Co. LLC, Virtus ETF Advisers LLC, and SG Americas Securities LLC. Company insiders that have bought Frequency Therapeutics stock in the last two years include James E Flynn, Joel S Marcus, and Marc A Cohen.
View insider buying and selling activity for Frequency Therapeutics
.

How do I buy shares of Frequency Therapeutics?

Shares of FREQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Frequency Therapeutics' stock price today?

One share of FREQ stock can currently be purchased for approximately $23.75.

How big of a company is Frequency Therapeutics?

Frequency Therapeutics has a market capitalization of $736.49 million and generates $28.95 million in revenue each year. The company earns $-18,750,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Frequency Therapeutics employs 33 workers across the globe.

What is Frequency Therapeutics' official website?

The official website for Frequency Therapeutics is www.frequencytx.com.

How can I contact Frequency Therapeutics?

Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY 2ND FLOOR, WOBURN MA, 01801. The company can be reached via phone at 866-389-1970 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.